Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Immunovant CEO Peter Salzmann sold 4,460 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On October 9, 2024, Immunovant CEO Peter Salzmann sold 4,460 shares of Immunovant common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of 8,281 restricted stock units (RSUs) on October 1, 2024.
- The shares were sold at a weighted average price of $29.56, with individual transactions ranging from $29.28 to $29.85 per share.
- Following the transaction, Salzmann directly owns 1,003,884 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't inherently indicate positive or negative sentiment.
Industry Context
Executive stock sales are a common occurrence, often related to compensation and tax planning. Monitoring these transactions can provide insights into management's perspective on the company's valuation.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, although it is a common practice for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| March 19, 2021 | Peter Salzmann was granted 132,500 restricted stock units. |
| March 23, 2021 | Form 4 filed reporting the grant of 132,500 restricted stock units. |
| October 1, 2024 | 8,281 restricted stock units vested. |
| October 9, 2024 | Peter Salzmann sold 4,460 shares of Immunovant common stock. |
| October 11, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.